News Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
16.17 ^USD	+0.87%		+1.06%	+10.75%

May. 07	HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating	MT
May. 06	Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating	May. 07	MT
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Day One Reports First Quarter 2024 Financial Results and Corporate Progress	May. 06	GL
North American Morning Briefing : Stock Futures -2-	May. 06	DJ
Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing	May. 06	MT
Day One Biopharmaceuticals Insider Sold Shares Worth $1,415,707, According to a Recent SEC Filing	May. 06	MT
North American Morning Briefing : Investors Brace -2-	Apr. 29	DJ
Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating	Apr. 24	MT
Transcript : Day One Biopharmaceuticals, Inc. - Special Call	Apr. 24
Day One Biopharmaceuticals : Corporate Presentation - April 2024	Apr. 24	PU
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor	Apr. 23	GL
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor	Apr. 23	AQ
Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma	Apr. 23	CI
Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment	Apr. 23	MT
Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval	Apr. 23	DJ
JPMorgan Raises Price Target on Day One Biopharmaceuticals to $36 From $32, Maintains Overweight Rating	Apr. 22	MT
Day One Biopharmaceuticals Insider Sold Shares Worth $322,166, According to a Recent SEC Filing	Feb. 29	MT
Piper Sandler Cuts Price Target on Day One Biopharmaceuticals to $40 From $45, Maintains Overweight Rating	Feb. 28	MT
Wedbush Adjusts Day One Biopharmaceuticals' Price Target to $33 From $35, Keeps Outperform Rating	Feb. 27	MT
Goldman Sachs Cuts Price Target on Day One Biopharmaceuticals to $44 From $50, Maintains Buy Rating	Feb. 27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Summary

Filters